Use of Advanced Systemic Therapy in Patients with Moderate to Severe Atopic Dermatitis in the TARGET-DERM Registry

Challenge

Despite the availability of multiple advanced systemic therapies for moderate-to-severe AD, real-world data on how these agents are actually being used across patient subgroups—including which patients receive them, how quickly they progress to AST, and what proportion remain undertreated—were limited.

Solution

The TARGET-DERM AD registry was analyzed to characterize AST utilization patterns across adult and adolescent patients, identifying predictors of AST initiation and quantifying the proportion of disease-severity-eligible patients who remained AST-naïve.

Impact

Establishing that a substantial proportion of patients with severe AD remain AST-naïve despite eligibility—particularly among those with lower insurance coverage—provides real-world evidence of the treatment access gap, directly informing commercial strategy and health equity commitments for AD biologic and JAK inhibitor programs.